The research, led by Ziruo Sun, Jinliang Wang, Zhigao Bu and colleagues at the Harbin Veterinary Research Institute of the Chinese Academy of Agricultural Sciences, began with a systematic search for the host machinery that rabies virus depends on to invade cells. In a previous genome-wide screen, the team had used 64,755 small interfering RNAs targeting 21,585 human genes in HEK293 cells to identify host factors required for rabies virus replication. Among the hits were sixteen genes related to potassium channels, and the strongest effect came from silencing KCNMA1, the gene that encodes the pore-forming subunit of the large conductance calcium- and voltage-activated potassium channel known as KCa1.1, a seven-transmembrane protein sitting in the plasma membrane.

To confirm that this channel genuinely matters for infection, the researchers knocked down KCa1.1 expression in both mouse neuroblastoma N2a cells and human HEK293 cells using specific siRNAs. Quantitative PCR verified that the channel’s mRNA was substantially reduced, and when the silenced cells were infected with a recombinant rabies virus strain expressing enhanced green fluorescent protein, the amount of infectious virus released into the culture supernatant dropped significantly at both 24 and 48 hours after infection. The team then turned to paxilline, a selective chemical inhibitor of KCa1.1 that binds the inner pore of the channel and blocks potassium conductance. In N2a, HEK293, and human SK-N-SH neuroblastoma cells, paxilline had no effect on cell viability but suppressed rabies virus replication in a clear dose-dependent manner, and time-course experiments confirmed the inhibition persisted across the tested period.

Because KCa1.1 is expressed primarily at the plasma membrane, the investigators hypothesized that it might act during viral entry rather than during later stages of the viral life cycle. Entry involves two separable steps: attachment of virus particles to the cell surface and their subsequent internalization. By incubating cells with virus at 4 degrees Celsius, a temperature that permits binding but prevents internalization, and then quantifying attached viral RNA, the team showed that neither KCa1.1 silencing nor paxilline treatment changed how much virus bound to cells. When the temperature was shifted to 37 degrees to allow entry, however, and surface-bound virus was stripped away with trypsin before analysis, the amount of viral RNA inside treated or silenced cells fell dramatically. A complementary microscopy assay, which labeled viral glycoprotein under conditions that distinguish particles remaining on the surface from those that had entered, showed that paxilline-treated cells accumulated more virus on their surface while their total particle count stayed the same. Together, these experiments demonstrated that activated KCa1.1 is specifically required for the internalization step of rabies virus entry.

A co-immunoprecipitation assay revealed that KCa1.1 does not physically interact with the rabies virus glycoprotein, the viral surface protein that drives attachment and clathrin-mediated endocytosis. That result pointed to an intermediary. Prior work had shown that KCa1.1 assembles into macromolecular complexes with voltage-gated calcium channels, including Cav1.2, and that calcium influx through these channels can activate KCa1.1. Notably, Cav1.2 was the only calcium channel that emerged from the team’s earlier genome-wide screen. Co-immunoprecipitation confirmed a specific interaction between Cav1.2 and KCa1.1, and silencing Cav1.2 in N2a and HEK293 cells significantly reduced rabies virus titers, establishing that the L-type calcium channel is also required for productive infection.

The mechanistic picture became sharper when the researchers examined the role of the viral glycoprotein itself. Co-immunoprecipitation showed that Cav1.2 specifically interacts with the rabies virus glycoprotein, and a pull-down assay using purified virus particles demonstrated that Cav1.2 captures rabies virions in a dose-dependent manner. Binding assays revealed that Cav1.2 silencing or blockade did not reduce how much virus attached to cells, but internalization assays showed far less viral RNA inside treated cells. In other words, the glycoprotein engages Cav1.2, and this engagement is required to activate the channel and trigger the internalization machinery, even though the virus still docks normally on the cell surface when the channel is disabled.

The team also identified the downstream cellular process that the channel axis manipulates. Rabies virus enters cells through clathrin-mediated endocytosis with the help of actin, and previous work had shown that KCa1.1 promotes influenza virus entry by regulating F-actin polymerization. Using phalloidin staining to visualize filamentous actin, the researchers found that rabies virus entry induces F-actin polymerization in HEK293 cells, and that this polymerization was markedly reduced when Cav1.2 or KCa1.1 were knocked down or when cells were treated with diltiazem or paxilline. The authors therefore propose a sequential model: rabies virus glycoprotein binds Cav1.2 and triggers its activation; activated Cav1.2 then interacts with and activates KCa1.1; and activated KCa1.1 drives F-actin polymerization that powers the internalization of the virus particle.

The therapeutic implications rest on diltiazem, a benzothiazepine-class L-type calcium channel blocker approved in the United States in 1982 and long prescribed for hypertension, angina, and atrial arrhythmias. In cell culture, diltiazem blocked rabies virus infection in a dose-dependent manner without affecting viability, and four other FDA-approved Cav1.2 antagonists, the phenylalkylamine verapamil and the dihydropyridines nifedipine, nicardipine, and nimodipine, also inhibited the virus in vitro. The decisive test came in mice. Six-week-old C57BL/6J mice were inoculated intramuscularly with ten 50 percent mouse lethal doses of the rabies street virus GX/09, and six hours later they began receiving daily intramuscular injections of diltiazem at 25 or 50 milligrams per kilogram, or a phosphate buffer control. All 19 control mice died within 9 to 16 days with typical rabies signs such as body tremors and hind limb paralysis. At the lower dose, 5 of 19 mice survived, roughly 26 percent, while at 50 milligrams per kilogram, 13 of 19 mice survived, approximately 70 percent, and the survivors remained completely asymptomatic throughout a 28-day observation period.

Measurements of viral burden supported the idea that diltiazem works by blocking entry before the virus reaches the brain. No viral RNA was detectable in the brains of treated or control mice at day 4, but by day 6, viral RNA was present in all six control animals examined and in only two of six diltiazem-treated animals, and immunohistochemistry at day 8 detected rabies antigen in all control brains but only one of three treated brains. When the researchers delayed diltiazem administration until days 6 and 7, after viral replication was already underway in the brain, they observed no significant reduction in brain viral RNA, indicating that the drug’s protection is unlikely to stem from direct suppression of established central nervous system infection. Notably, the 50 milligram per kilogram mouse dose corresponds, after body surface area normalization under FDA guidelines, to a human equivalent dose of roughly 4 milligrams per kilogram, or about 240 milligrams per day for a 60-kilogram adult, which falls squarely within the range already used clinically for cardiovascular indications.

The authors argue that diltiazem could serve as an affordable, mass-produced complement to existing post-exposure prophylaxis, offering a stopgap where rabies immunoglobulin is unavailable and a potential enhancement where it is not, since it is estimated that only 1 to 10 percent of category III exposure patients currently receive the recommended treatment. The findings also extend a growing body of evidence that ion channels are conserved entry factors for diverse viruses: Cav1.2 has been implicated in SARS-CoV-2 and influenza virus entry, KCa1.1 in influenza virus endocytosis, and diltiazem has shown activity against rotavirus, porcine reproductive and respiratory syndrome virus, and porcine deltacoronavirus. With no approved drugs currently targeting KCa1.1, the potassium channel remains a target for future drug development, while Cav1.2, already served by three structural classes of clinically validated antagonists, stands out as a promising foundation for broad-spectrum antiviral strategies. Further studies will be needed to evaluate the in vivo efficacy of the other calcium channel blockers and to determine whether diltiazem concentrations in the central nervous system reach antiviral levels, but the prospect of repurposing a decades-old cardiovascular pill against one of humanity’s most lethal pathogens gives the global effort to eliminate rabies deaths a genuinely new weapon to test.

Subject of Research: Repurposing the calcium channel blocker diltiazem to block rabies virus entry via the Cav1.2-KCa1.1 ion channel axis

Article Title: Targeting the Cav1.2-KCa1.1 axis prevents rabies virus internalization and protects against lethal infection

Article References: Sun, Z., Wang, J., Wen, Z., Shuai, L., Sun, W., Yang, M., Wang, J., Chen, J., Mi, T., Zhou, X., Zhou, P., Lv, N., Zhao, Z., Ge, J., Chen, W., Wang, X., Wang, C., Bu, Z., & Wang, J. (2026). Targeting the Cav1.2-KCa1.1 axis prevents rabies virus internalization and protects against lethal infection. PLOS Pathogens, 22(10), e1014675. https://doi.org/10.1371/journal.ppat.1014675

Image Credits: AI Generated

DOI: 10.1371/journal.ppat.1014675

Keywords: rabies virus, diltiazem, Cav1.2, KCa1.1, ion channels, viral entry, endocytosis, drug repurposing, F-actin polymerization, post-exposure prophylaxis, PLOS Pathogens, antiviral therapy

The story begins with a gene called plasmolipin, or pllp, which encodes an endosomal membrane protein found at strikingly high levels in a specialized population of gut cells known as lysosome-rich enterocytes, or LREs. These cells are the protein-processing workhorses of the fish intestine, and they also perform the same duty in neonatal mammals, where they swallow and digest intact dietary proteins wholesale. In zebrafish, when pllp is knocked out, LREs fail to differentiate properly, protein absorption collapses, and mutant larvae show sharply reduced survival. On its face, this is a devastating loss-of-function mutation, the kind of genetic damage that developmental biologists routinely generate in the lab and that natural selection would normally prune from a population.

But the researchers noticed something unexpected when they kept the mutants alive. By carefully raising pllp homozygous mutants through to adulthood and then crossing them with one another over multiple generations, the colony’s survival and growth rates crept back upward. Remarkably, the recovered fish handled a low-protein diet with ease, despite still carrying the broken gene. This was not a laboratory artifact or a hidden rescue construct; the fish remained mutants at pllp, yet their bodies had found another route to the same physiological destination. The question became how a population could climb out of a functional hole without ever repairing the original lesion.

To dissect the mechanism, the team assembled a three-way comparison that serves as the analytical backbone of the study. They generated a brand-new pllp mutant allele, freshly crippled and still suffering the full consequences of protein malabsorption. They compared it with the older, adapted pllp allele that had been inbred across generations. And critically, they included genetically related wild-type fish as the baseline, ensuring that any differences attributed to adaptation would not simply reflect the accumulated genetic drift of a laboratory strain. This design allowed the researchers to separate what the mutation destroys from what subsequent evolution rebuilds.

Transcriptome profiling across these groups revealed a clear signature of adaptation. The adapted pllp mutants showed upregulation of the endocytic components that LREs use to engulf dietary proteins, essentially turning up the dial on the cell’s internal swallowing apparatus. Quantitative protein absorption assays then confirmed that this transcriptional shift had real functional teeth: the adapted mutants absorbed protein at levels that exceeded even the wild-type fish. In other words, evolution had not merely restored the lost function to its original set point. It had pushed the intestinal absorptive machinery into a state of hyperactivation, compensating for the defective differentiation of LREs by making whatever absorptive capacity remained work overtime.

That hyperactivation, however, came with a hidden cost that the study also illuminates. Cells that engulf enormous quantities of material from the intestinal lumen inevitably expose the animal to a heavier load of environmental antigens, including bacterial products and undigested macromolecules. Consistent with this, the adapted mutants displayed transcriptional regulation of immune genes, suggesting that the immune system had been recalibrated in parallel with the digestive one. The authors propose that these immune adjustments may be a crucial part of why the adapted fish survive so well, buffering them against the heightened antigenic exposure that comes with a gut running in absorptive overdrive. Adaptation, in this view, is not a single fix but a coordinated physiological package.

Perhaps the most provocative result concerns how these phenotypes emerge over time. Genetic analyses indicated that the improved survival and growth did not appear suddenly in one generation. Instead, they accumulated gradually, generation after generation, as the inbred mutant line was propagated. This stepwise trajectory implies that multiple genetic changes, likely spread across the genome, contribute incrementally to the adaptive phenotype, each one nudging survival a little higher until the population as a whole regains robust fitness. Genome-wide transcriptional profiling captures the endpoint of that process: a broad, stable reprogramming of intestinal and immune gene expression that underlies the organism-level recovery.

Even more striking is the study’s evidence that this adaptation is repeatable. When the researchers generated an entirely independent pllp mutant allele and subjected it to the same regimen of inbreeding and natural selection, the same divergent phenotypes re-emerged. The recovery of survival and growth on a low-protein diet was not a lucky accident confined to one lineage’s genetic background. It recurred, suggesting that the paths evolution can take to solve the problem of protein malnutrition in this system are constrained and reproducible, funneling independent lineages toward similar transcriptional and physiological solutions. Recurrent adaptation of this kind hints at deep regularities in how genomes can be rewired to compensate for a specific functional deficit.

The broader implications stretch beyond fish biology. LREs mediate protein uptake in neonatal mammals, so understanding how their endocytic and absorptive programs can be transcriptionally tuned may inform questions about early-life nutrition, gut maturation, and the interplay between digestion and mucosal immunity. The study also speaks to a long-standing debate in evolutionary biology about whether adaptation proceeds through large single-step changes or through the gradual accumulation of many small effects. Here, the gradual, multigenerational emergence of the phenotype, tracked alongside its recurrent appearance in an independent allele, argues for a distributed, polygenic route in which genome-wide expression changes are the substrate on which selection acts.

What makes the work resonate beyond its technical achievements is the picture it paints of living systems as capable of engineering their own workarounds. A broken gene that should spell starvation instead becomes the starting point for an evolutionary project, one in which the gut learns to absorb more than it ever did and the immune system learns to tolerate the consequences. The zebrafish in these experiments did not wait for their DNA to be repaired. They rewired the instructions around it, generation by generation, until protein malnutrition was a problem they had simply outgrown. In doing so, they offer one of the clearest demonstrations yet that stable, heritable improvements in organ function can be built from the raw material of genome-wide transcriptional change, assembled under the patient pressure of natural selection.

Subject of Research: Gradual, recurrent transcriptional adaptation to protein malnutrition in zebrafish lacking the endosomal gene plasmolipin

Article Title: Genome wide transcriptional changes underlie gradual and recurrent adaptation to protein malnutrition in zebrafish

Article References: Genome wide transcriptional changes underlie gradual and recurrent adaptation to protein malnutrition in zebrafish. (n.d.). https://doi.org/10.1371/journal.pgen.1012071

Image Credits: AI Generated

DOI: 10.1371/journal.pgen.1012071

Keywords: zebrafish, protein malnutrition, lysosome-rich enterocytes, plasmolipin, transcriptomics, endocytosis, intestinal absorption, adaptation, genetics, immunity, natural selection, PLOS Genetics

A team of researchers led by Yue Gong and Wei Lv engineered a family of biomimetic nanocarriers in which mesoporous silica nanoparticles were coated with membranes harvested from mesenchymal stem cells and loaded with the chemotherapy drug doxorubicin. Mesenchymal stem cells were chosen as the membrane source for good reason: these cells naturally exhibit tropism toward injured and tumor-associated tissues and can migrate across the blood-brain barrier toward glioma lesions. By wrapping the synthetic silica cores in stem cell membranes, the researchers hoped to transfer membrane-associated features involved in endothelial interaction, immune tolerance, and tumor homing onto the drug carriers. Crucially, unlike whole-cell therapies, the biological functions of these membrane-coated nanoparticles arise from retained surface proteins rather than paracrine secretion, offering a controllable and drug-loaded platform.

The truly novel element of the study, however, was its systematic interrogation of particle morphology. While the overwhelming majority of brain-targeted nanodelivery research has focused on optimizing particle size, surface charge, ligand density, and pore architecture, the influence of shape has remained poorly characterized. Using a template-based synthesis in which increasing concentrations of the surfactant CTAB drove the formation of progressively elongated particles, the team produced three distinct geometries: spheres with an aspect ratio of approximately 1, short rods with an aspect ratio of about 1.5, and long rods with an aspect ratio near 3. Transmission electron microscopy confirmed uniform, well-defined particles with highly ordered porous channels, and dynamic light scattering showed hydrodynamic diameters of 188.3, 192.4, and 254.1 nanometers respectively, all with low polydispersity indices and negative zeta potentials that favored subsequent membrane coating.

To ensure that any biological differences could be attributed to shape rather than to confounding formulation variables, the researchers carefully standardized everything else. Doxorubicin was loaded by electrostatic adsorption at a drug-to-particle ratio of 1:1, yielding a loading level of approximately 43 percent across all three morphologies. After coating, western blot analysis confirmed that key mesenchymal stem cell membrane proteins, including CD47, CXCR4, and VLA-4, were preserved on the surface of all coated particles, with the membrane reference protein ATP1A1 showing comparable signals across formulations. In vitro release profiles were similarly indistinguishable, with cumulative doxorubicin release reaching approximately 26 percent within 12 hours and no burst release, and the particles remained stable in storage for over a week. The stage was thus set for a clean comparison of geometry alone.

The first hint of a shape effect emerged from multiple-particle tracking, a sensitive optical technique that captures the motion trajectories of individual nanoparticles in fluid. Spherical particles moved within a relatively limited area, whereas both short-rod and long-rod particles displayed a broader movement range. Quantitative analysis revealed that rod-shaped particles exhibited higher mean square displacement, average velocity, and diffusion coefficient than their spherical counterparts, with the long rods showing the greatest motility of all. The researchers attribute this enhanced motility to translational-rotational coupling and hydrodynamic effects associated with shape anisotropy. In practical terms, faster-diffusing particles have a higher probability of making contact with target cells after being transported through the bloodstream, which sets the stage for more efficient cellular interaction and transmembrane transport.

Those predictions held up in cell-based experiments. In both bEnd.3 brain endothelial cells and GL261 glioma cells, fluorescence signals intensified with increasing aspect ratio, and the long rod-shaped particles were taken up significantly more than the other two groups. Importantly, uncoated silica particles showed the same morphology-dependent uptake pattern, demonstrating that particle geometry itself makes an important contribution to cellular internalization rather than the effect being purely a product of the membrane coating. In a Transwell model of the blood-brain barrier, in which endothelial cells formed a tight barrier confirmed by transepithelial electrical resistance measurements above 200 ohms per square centimeter, all three formulations crossed to some degree, but the long rods achieved the highest transport efficiency at every time point tested. In three-dimensional GL261 tumor spheroids, the contrast was even more striking: spherical particle fluorescence was largely confined to the outer shell of the spheroid, fading beyond 40 micrometers of depth, while long-rod fluorescence remained strong even in the deepest scanned layers.

To understand the mechanism, the researchers turned to bio-transmission electron microscopy and surface plasmon resonance. The electron micrographs revealed that spherical particles typically made localized membrane contact and were internalized through small flask-shaped invaginations enclosing single particles, whereas rod-shaped particles formed extended contact along the cell membrane with more pronounced membrane wrapping and invagination structures. Surface plasmon resonance measurements quantified these differences: long rods showed the highest association rate constant and the lowest dissociation rate constant, yielding the lowest equilibrium dissociation constant and therefore the fastest, most stable binding to the endothelial cell surface. Spherical particles, by contrast, bound weakly, with an equilibrium dissociation constant of 1.07 times ten to the minus four molar. Endocytosis inhibitor experiments added another layer of insight. Uptake of all formulations was energy-dependent, dropping sharply at 4 degrees Celsius, but spherical particles were internalized mainly through lipid raft and caveolae-related pathways, while rods increasingly engaged clathrin-mediated endocytosis as their aspect ratio grew, suggesting that stronger initial binding drives more complex and efficient entry routes.

The decisive test came in living animals. In mice bearing intracranial GL261 gliomas, fluorescently labeled long-rod particles produced the strongest cerebral fluorescence signal throughout a 24-hour observation window, and ex vivo analysis of isolated brains confirmed the highest brain-associated fluorescence in this group, reaching 4.014 times ten to the seventh in quantitative region-of-interest analysis. The retained CD47 on the membrane coating likely helped the particles evade rapid immune clearance, prolonging circulation and supporting accumulation. In the therapeutic study, mice received five intravenous doses of each formulation, and bioluminescence imaging tracked tumor growth over four weeks. Tumors in the long-rod treatment group showed a 46.61 percent decrease in bioluminescence intensity on day 28 compared with day 14, and histological staining confirmed the greatest induction of tumor cell apoptosis and the strongest suppression of the proliferation marker Ki67 in this group.

Survival data delivered the most clinically resonant result. Median survival times were 25.5 days for saline-treated mice, 26.5 days for free doxorubicin, and 28.5 days for both the spherical and short-rod formulations, but mice receiving the long-rod particles survived a median of 37.0 days, a benefit that remained statistically significant after rigorous correction for multiple comparisons. Two mice in the long-rod group were still alive at the end of the observation period. Safety testing in healthy mice showed stable body weight, normal liver and kidney biochemistry, and no pathological abnormalities on organ histology, indicating no obvious systemic toxicity under the tested regimen.

The authors are careful to frame their conclusions appropriately. The shape effects were evaluated using only three morphologies within a single mesoporous silica platform, and the coated and uncoated series were assessed in independent experimental sets, so the independent contribution of the membrane coating and its potential interaction with geometry remain to be quantitatively resolved. Future work incorporating atomic force microscopy, membrane mechanics measurements, and computational simulations of membrane wrapping will be needed to fully explain the biophysics at play. Even so, the message is clear and potentially transformative: in the rational design of brain-targeted drug delivery, particle shape is not a cosmetic detail but a first-order optimization parameter. For a disease where nearly every therapeutic advance is thwarted by the blood-brain barrier, the demonstration that simply stretching a nanoparticle into a rod can dramatically improve its journey from bloodstream to brain tumor offers an elegant, manufacturable, and deeply counterintuitive new lever for the fight against glioma.

Subject of Research: Shape-dependent transmembrane transport of mesenchymal stem cell membrane-coated mesoporous silica nanoparticles for enhanced anti-glioma drug delivery across the blood-brain barrier

Article Title: Shape-dependent transmembrane transport of mesenchymal stem cell membrane-coated mesoporous silica nanoparticles enhances anti-glioma therapy

Article References: Shape-dependent transmembrane transport of mesenchymal stem cell membrane-coated mesoporous silica nanoparticles enhances anti-glioma therapy. (n.d.). https://doi.org/10.1016/j.mtbio.2026.103703

Image Credits: AI Generated

DOI: 10.1016/j.mtbio.2026.103703

Keywords: glioma, blood-brain barrier, mesenchymal stem cell membrane, mesoporous silica nanoparticles, particle shape, doxorubicin, biomimetic nanocarriers, drug delivery, endocytosis, surface plasmon resonance, nanomedicine, brain tumor therapy

The loophole is the folate receptor, a cell-surface protein whose normal job is to snag vitamin B9 from the bloodstream and pull it inside the cell. In a range of malignancies, including breast, ovarian, lung, colorectal, pancreatic, and cervical cancers, tumor cells crank up production of this receptor to feed their rapid division. By chemically attaching folate to the surface of a chitosan nanoparticle, drug designers create a particle that cancer cells actively import through folate receptor-mediated endocytosis, the same process the cells use to harvest the vitamin itself. The result is a delivery vehicle that does not merely drift into tumors passively but is actively swallowed by the malignant cells, concentrating the toxic payload where it is needed and sparing healthy tissue that expresses little of the receptor.

Chitosan itself brings an unusually attractive set of properties to the partnership. Extracted from chitin, the structural polymer of crustacean shells, it is biocompatible, biodegradable, and positively charged at physiological pH, which allows it to form stable nanoparticles through mild, water-based chemistry rather than harsh organic solvents. It is also mucoadhesive, meaning it clings to biological surfaces, and chemically versatile, with amine groups along its backbone that provide convenient handles for attaching targeting ligands like folate. The review emphasizes that this chemical versatility is what makes the platform so adaptable: researchers can tune particle size, surface charge, and drug-loading capacity by adjusting the degree of deacetylation of the polymer, the molecular weight of the chitosan chains, and the density of folate conjugation on the surface.

The published literature assembled in the review shows how broadly this design has already been tested in laboratory and preclinical settings. Folate-conjugated chitosan nanoparticles have been loaded with 5-fluorouracil for site-targeted colorectal delivery, with cytarabine for improved killing of MCF-7 breast cancer cells, with dasatinib for folate receptor targeting, with gemcitabine for lung cancer, and with paclitaxel for ovarian cancer cells. Natural compounds have joined the roster as well, including thymoquinone aimed at ovarian cancer, curcumin analogues, osthole delivered to pancreatic and colon cancer models, and an apolar acetogenin that inhibits cervical cancer cell proliferation. In many of these studies, the folate-targeted formulation outperformed its non-targeted counterpart in cellular uptake, cytotoxicity, and sustained drug release, precisely the profile that precision oncology demands.

Several studies highlighted in the review push the platform beyond simple one-drug, one-target designs. Folate-tagged chitosan-functionalized gold nanoparticles have been used to deliver doxorubicin to breast and cervical cancer cells and 5-fluorouracil to folate receptor-positive tumors. Chitosan-folate decorated carbon nanotubes have been engineered for site-specific lung cancer delivery, and folic acid-conjugated magnetic oleoyl-chitosan nanoparticles allow doxorubicin to be released in a controlled fashion while the magnetic core opens the possibility of image-guided delivery. Dual-drug systems are also appearing, such as folate-targeted chitosan nanoparticles co-delivering 5-fluorouracil and methotrexate, exploiting the synergy between two antimetabolites. Stimuli-responsive variants add another layer of sophistication: glutathione-responsive, folate receptor-targeted nanoparticles have been designed to unload their cargo only after entering the reducing environment of the tumor cell interior, and pH-responsive folate-conjugated chitosan systems exploit the acidity of the tumor microenvironment to trigger release specifically at the disease site.

The review also situates folate-chitosan systems within the broader movement toward smart, multifunctional nanocarriers, pointing to recent work on MXene quantum dot polymer nanocomposites as an example of where the field is heading. The common threads, the authors argue, are surface engineering, multifunctionality, controlled release, and rigorous safety evaluation. A modern nanocarrier is expected not just to carry a drug but to respond to its surroundings, potentially carry a diagnostic agent alongside the therapeutic payload, and degrade into harmless byproducts. Chitosan’s track record in this respect is strong: it is already used in approved medical products, and clinical trial analyses of chitosan-based biomaterials suggest a regulatory pathway that many exotic nanomaterials lack.

Pharmacokinetics and biodistribution are where targeted nanocarriers must ultimately prove themselves, and the review addresses these dimensions directly. Compared with non-targeted formulations, folate-functionalized chitosan nanoparticles have the potential to enhance cellular uptake, provide sustained and controlled drug release, improve anticancer efficacy, and reduce systemic toxicity. The active targeting mechanism complements the enhanced permeability and retention effect, the passive tendency of nanoparticles to accumulate in leaky tumor vasculature, by adding a receptor-driven import step once the particles reach the tumor. This dual mechanism, passive accumulation followed by active cellular uptake, is one reason the platform has attracted sustained attention across so many tumor types.

Yet the review is notably candid about the obstacles standing between the laboratory bench and the oncology clinic. Reproducibility of nanoparticle synthesis remains a stubborn problem, as small batch-to-batch variations in polymer properties can alter particle behavior in clinically meaningful ways. Formulation stability during storage, immunogenicity concerns, and scalability of manufacturing all require careful attention before regulatory agencies will approve a folate-chitosan product. Perhaps the most biologically thorny challenge is interpatient variability in folate receptor expression: the entire targeting strategy depends on the tumor displaying the receptor, and expression levels differ between patients, between tumor types, and even between regions of the same tumor. The authors argue that successful clinical development will require careful attention to all of these translational challenges, not just the elegant chemistry of the particles themselves.

What emerges from the review is a picture of a platform that is biologically relevant, chemically tunable, and increasingly sophisticated, but still awaiting its decisive clinical test. The preclinical evidence base is broad, spanning conventional cytotoxics, repurposed drugs, and natural products, and the safety profile of the underlying polymer is well characterized. If the fields of formulation science and regulatory science can catch up with the chemistry, folate-modified chitosan nanocarriers could move from a versatile laboratory tool to a genuine instrument of precision oncology, delivering lethal payloads to the cells that display the right molecular address while leaving the rest of the body largely untouched.

Subject of Research: Folate-functionalized chitosan nanoparticles for targeted anticancer drug delivery

Article Title: Folate-modified chitosan nanocarriers in precision oncology: molecular engineering, targeted drug delivery, and clinical perspectives

Article References: Khan, M. S., & Almalki, W. H. (2026). Folate-modified chitosan nanocarriers in precision oncology: molecular engineering, targeted drug delivery, and clinical perspectives. Medical Oncology, 43(10), Article 282. https://doi.org/10.1007/s12032-026-03415-2

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03415-2

Keywords: chitosan nanoparticles, folate receptor, targeted drug delivery, precision oncology, nanomedicine, chemotherapy, drug delivery, biodegradable polymers, cancer therapy, endocytosis, controlled release, clinical translation

The opacity of the plant cell is not accidental. Unlike animal cells, plant cells are wrapped in thick, refractive cell walls and packed with autofluorescent organelles such as chloroplasts, both of which severely limit optical penetration and clarity. Traditional confocal microscopy therefore struggles to capture the transient, nanoscale events of vesicle formation and fusion, leaving researchers with static snapshots or ensemble averages that obscure true molecular kinetics. The review, authored by Yanyan Zhang, Changwen Xu, and colleagues at Beijing Forestry University, identifies three persistent blind spots: the unknown in vivo stoichiometry and dwell time of endocytic complexes at the plasma membrane, the invisible dynamics of sterol-rich membrane nanodomains smaller than 100 nanometers, and the elusive sorting logic of unconventional protein secretion, in which cytoplasmic proteins reach the cell surface without any canonical signal peptide.

Consider the endocytic machinery itself. Genetic screens have assembled a parts list that includes the evolutionarily ancient AP-2 complex and the plant-specific TPLATE complex, both of which recruit clathrin to sites of membrane internalization. But the structural view conceals a kinetic question that current instruments cannot easily answer: does the octameric TPLATE complex assemble incrementally at the membrane or arrive pre-formed, and how do these complexes uncoat within the fleeting seconds between vesicle scission and fusion with the trans-Golgi network? The review notes that when salt stress strikes Arabidopsis, fusion between multivesicular bodies and vacuoles is impaired while vacuolar remodeling boosts the compartmentalization of sodium ions, a process central to salt tolerance. Knowing the players, the authors argue, is not the same as knowing the tempo of their performance.

To overcome the optical barrier, the review synthesizes a suite of labeling strategies tailored to plant constraints. Among the most versatile is pHluorin, a pH-sensitive variant of green fluorescent protein that exploits the steep pH gradient inside plant endomembranes, from the near-neutral endoplasmic reticulum at roughly pH 7.1 to the acidic trans-Golgi network at about pH 6.1 and the lytic vacuole below pH 5.5. As a vesicle matures and acidifies, pHluorin fluorescence dims accordingly, allowing researchers to measure the exact time a vesicle takes to travel from the TGN to the multivesicular body. Engineered derivatives such as PEpHluorin and PRpHluorin extend this capability, and FRET-based ratiometric probes are now pushing detection into the harsh acidic environments where conventional pHluorin is quenched.

For tracking individual molecules with high signal-to-noise, the review highlights self-labeling protein tags, chief among them HaloTag, a 33-kilodalton engineered enzyme that covalently binds dye-conjugated ligands. Because its ester-bond linkage avoids the thioether chemistry that promotes photobleaching, HaloTag offers an exceptionally high photon budget, and protein engineering that removes oxidation-prone methionine residues near the fluorophore can further improve photostability severalfold. That resilience allows HaloTag-labeled proteins to withstand the intense excitation light needed to image deep inside plant tissues, making it well suited for long-term monitoring and single-particle tracking of membrane protein dynamics at nanometer scale. The authors caution that ligand cost, cell-wall permeability, and potential photodamage still limit routine use, and they call for plant-specific optimization and photoactivatable ligand systems.

A third dimension, quite literally, comes from fluorescent timers, molecular chronometers that shift color as they mature, thereby recording the age of a protein. Static imaging cannot distinguish newly synthesized cargo from recycled pools, but timers such as DsRED-E5, which transitions from green through yellow to red, can map sorting fates over time. The technology has limits: tandem fluorescent timer systems suffer reduced dynamic range and cannot resolve degradation events with half-lives shorter than 30 minutes, while the photoconvertible protein Dendra2 loses activity in acidic vacuoles and mCherry maturation is sensitive to diurnal temperature swings that plants inevitably experience. Newer probes such as mEosEM, which matures within 15 minutes and withstands chemical fixation, are closing that gap for rapid secretory dynamics.

Perhaps the most radical departure from overexpression-based imaging is CRISPR-mediated bioimaging, which visualizes genomic loci and transcripts at their endogenous levels. By fusing catalytically inactive dCas9 to fluorescent markers, researchers can follow chromosomal dynamics in living cells without distorting protein stoichiometry, and the CRISPR-SunTag system amplifies signals enough to detect low-abundance mRNAs that standard dCas9-EGFP constructs miss. Plant applications face real obstacles, including off-target binding in repeat-rich genomes and chloroplast autofluorescence that swamps weak endogenous signals, but far-red probes such as iRFP670 and two-photon excitation are steadily eroding those barriers. Complementing all of these genetically encoded tools, bio-orthogonal click chemistry attaches diminutive inert tags to lipids, glycans, and cell wall polysaccharides, avoiding the steric hindrance that bulky fluorescent proteins impose on small molecules, and enabling real-time visualization of pectin deposition during growth.

Visualization alone, however, is only half of the new paradigm; the other half is quantitative prediction through artificial intelligence. Fluorescence recovery after photobleaching, long the gold standard for measuring protein mobility, has traditionally relied on nonlinear least-squares fitting to idealized analytical models, an approach that plant tissues sabotage with refractive cell walls and large vacuoles that trap algorithms in local minima. DeepFRAP, a neural network trained on more than a million simulated recovery curves corrupted with realistic Poisson and Gaussian noise, learns to see through that noise and extract diffusion coefficients in milliseconds rather than seconds, eliminating operator bias and enabling high-throughput screening of hundreds of mutant lines for subtle trafficking defects. Similarly, deep learning tools such as ImFCSNet now extract diffusion coefficients from fluorescence correlation spectroscopy data using as few as 2,500 frames instead of the more than 50,000 previously required, cutting light exposure twentyfold and making live-cell quantitative mapping feasible in light-sensitive plant tissues.

Kymograph analysis, which compresses time-lapse video into two-dimensional space-time plots, illustrates how these quantitative methods can settle long-standing mechanistic debates. When applied to the G-protein regulator AtRGS1, kymographic signatures revealed that the bacterial flagellin fragment flg22 triggers rapid, short-lived endocytic events characteristic of clathrin-mediated endocytosis, whereas the endogenous danger signal Pep1 produces distinct trajectories linked to sterol-dependent endocytosis, the first direct evidence that plants use different endocytic routes to discriminate microbial from self-derived alarms. Kymography has likewise shown that blue light induces a dose-dependent increase in the lateral diffusion and dimerization of phototropin 1 at the plasma membrane, a shift absent in kinase-inactive mutants. The technique’s Achilles heel is throughput: in pollen tubes, where vesicle density exceeds 100 per square micrometer, manual tracing takes hours per cell and errors multiply as trajectories cross, which is precisely why the authors anticipate deep learning trace-linking tools to automate the analysis.

The review closes with a roadmap that extends beyond the microscope to the field. Vesicle kinetic parameters such as diffusion coefficients and membrane residence times, the authors propose, could serve as quantitative biomarkers for breeding, functioning as protein quantitative trait loci that link trafficking efficiency to stress tolerance and nutrient uptake. Coupling live-cell imaging with single-cell transcriptomics would reveal how transcriptional reprogramming of RAB GTPases and clathrin subunits reshapes trafficking networks in specific cell types during pathogen attack, forming a bidirectional feedback circuit between membrane behavior and gene expression. The authors also flag sobering caveats: deep learning models trained on simplified simulated data can hallucinate or miss rare trafficking events, a domain gap that demands robust adaptation algorithms, and cross-laboratory comparability of kinetic parameters remains unresolved without standardized benchmark datasets. If those challenges are met, the quantitative framework outlined here could rewrite plant cell biology textbooks and, more concretely, guide the development of crops that withstand salt, pathogens, and climate stress by tuning the nanoscale logistics inside their cells.

Subject of Research: Multimodal imaging and deep learning-based quantitative analysis of plant vesicular trafficking dynamics

Article Title: Unlocking the black box: multimodal imaging and quantitative analysis of plant vesicular trafficking

Article References: Zhang, Y., Xu, C., Zuo, X., Qian, H., Zhang, X., Lin, J., & Cui, Y. (2026). Unlocking the black box: multimodal imaging and quantitative analysis of plant vesicular trafficking. Advanced Biotechnology, 4(1), Article 8. https://doi.org/10.1007/s44307-026-00101-2

Image Credits: AI Generated

DOI: 10.1007/s44307-026-00101-2

Keywords: vesicular trafficking, plant cell biology, pHluorin, HaloTag, fluorescent timers, CRISPR imaging, click chemistry, DeepFRAP, FCS, kymography, deep learning, endocytosis

Trypanosomatid flagellates such as Trypanosoma brucei and T. cruzi have long fascinated cell biologists because their endocytic traffic is confined to a single invagination of the plasma membrane called the flagellar pocket. This unusual geometry makes them powerful models for testing how universal the principles of membrane trafficking really are. Previous work had catalogued many components of clathrin-mediated endocytosis in these parasites, but the composition and evolutionary standing of their ESCRT machinery remained incompletely resolved. In animals and fungi, a subcomplex called ESCRT-0, built around the Vps27/Hrs and STAM proteins, recognises ubiquitylated substrates and hands them to the downstream complexes. Whether trypanosomes possess anything comparable has been an open question.

The team approached the problem from two directions: comparative genomics across the eukaryotic tree and experimental biochemistry in the parasite itself. Using hidden Markov model searches and reciprocal best BLAST analyses, they surveyed hundreds of genomes from every major eukaryotic supergroup for orthologs of candidate sorting proteins. In parallel, they engineered procyclic-form T. brucei cells to express an endogenous GFP-tagged version of Vps23, the Tsg101 orthologue that anchors the ESCRT-I complex. Affinity purification followed by quantitative mass spectrometry then pulled down the proteins that travel with TbVps23 in living cells, allowing the researchers to confirm predicted partners and uncover unexpected ones.

The most striking biochemical discovery was that trypanosome ESCRT-I is not the canonical heterotetramer familiar from yeast and animals. Instead, the purification identified two novel Vps23-interacting proteins, encoded by adjacent open reading frames Tb927.11.2020 and Tb927.11.2030, that travel stoichiometrically with the core subunits. These proteins are specific to trypanosomes, with no obvious homologues outside the kinetoplastid lineage, and their association with Vps23 indicates that the trypanosome ESCRT-I subcomplex is a heteropentamer. The finding adds a new tier of compositional divergence to a complex long considered structurally conserved, and it underscores how evolutionary flexibility can be woven into even the most fundamental cellular machines.

Equally consequential is the team’s answer to the question of what serves as the trypanosome ESCRT-0 analogue. Rather than a Vps27/STAM pair, which the analyses confirmed is absent from most non-opisthokont lineages, the parasites employ Tom1, a protein carrying the VHS and GAT domains that is broadly distributed across eukaryotes. The researchers demonstrated that trypanosome Tom1, termed TbTom1, colocalises with TbVps23 at endosomal membranes and interacts with a kinetoplastid-specific partner protein the authors nicknamed Jerry, a multi-domain protein studded with three FYVE domains, lipid-binding modules that recognise endosomal phosphoinositides. Together, Tom1 and Jerry appear to fulfil the substrate-recognition role that ESCRT-0 plays in fungi and animals, but through entirely different molecular parts.

Structural predictions reinforced the ancient pedigree of this arrangement. AlphaFold3 modelling of TbTom1 revealed a compact, well-ordered VHS helical bundle linked to a GAT domain, closely superimposable on the VHS domain of human TOM-1, while the remaining regions of the protein are predicted to be intrinsically disordered. This architecture supports the authors’ proposal that Tom1 is the ancestral VHS-GAT-domain-containing cargo adaptor, present in the last common ancestor of eukaryotes and retained across supergroups, whereas the Vps27/Hrs-STAM system of ESCRT-0 is a later innovation restricted to animals and fungi. By mapping the occurrence of Tom1 and Jerry orthologues across the Euglenozoa, the researchers showed that Tom1 is universally retained within the phylum while Jerry is absent from diplonemids, tracing a lineage-specific layer of specialisation on top of a conserved core.

The experimental evidence connecting these proteins to endocytic function came from cellular phenotyping. Cells expressing tagged versions of TbTom1 or TbJerry showed significantly enlarged flagellar pockets, with morphometric analysis of DAPI-stained cells revealing a marked increase in pocket area compared with the parental line, and tagged TbJerry cells additionally displaying a subtle nozzle-like distortion of the pocket. Because the flagellar pocket is the sole site of endocytosis in trypanosomes, such expansion implies a direct perturbation of membrane uptake and trafficking throughput. The phenotypes were measured across individual cloned lines and validated by immunoblotting of endogenous tags, giving the morphological data a firm molecular footing.

Curiously, the machinery appears dispensable for parasite viability in laboratory culture. RNA interference targeting TbTom1 in bloodstream-form cells reduced transcript levels by roughly 65 percent yet left proliferation unimpaired over an eight-day course, and mass spectrometric profiling of the silenced proteome showed that overall protein composition shifted only modestly. Concanavalin A uptake assays, which track soluble cargo from the flagellar pocket through endosomes to the lysosome, proceeded indistinguishably in TbTom1-depleted cells and controls. The authors interpret this resilience as evidence of redundancy or adaptability within the trypanosome sorting network rather than irrelevance of Tom1, a pattern consistent with the plasticity that their comparative analyses document throughout the system.

Broadly, the study reframes how biologists should think about the early ESCRT machinery. Evidence that Tom1 functions within the ESCRT pathway of trypanosomes supplies the fourth eukaryotic supergroup in which such a role has been demonstrated, and the authors argue that Tom1, not Vps27/STAM, is likely part of the pan-eukaryotic early ESCRT apparatus. At the same time, the heteropentameric ESCRT-I complex and the kinetoplastid-restricted Jerry protein illustrate how individual lineages continue to elaborate and customise the machinery, echoing earlier discoveries such as the plant-specific FREE1 adaptor, whose orthologues the team also surveyed across embryophytes. Evolution, in this view, has conserved the skeleton of the sorting system while repeatedly rebuilding its sensory apparatus.

For parasitologists, the implications extend toward intervention. Trypanosomes depend on relentless endocytic turnover of their variant surface glycoproteins and invariant surface receptors to evade the immune system, and any component that is parasite-specific, such as the novel ESCRT-I subunits or Jerry, represents a potential Achilles heel that host proteins do not share. Conversely, the conserved Tom1-dependent pathway offers a benchmark against which the animal and fungal systems can be reinterpreted, potentially correcting an animal-centric bias that has coloured membrane trafficking research for decades. What this study makes clear is that the deepest lessons about how eukaryotic cells move their membranes may come not from yeast or human tissue culture, but from an ancient parasite whose cellular geography forces every molecular handoff to happen in one remarkable pocket of membrane.

Subject of Research: The composition and evolution of the ESCRT endosomal sorting system in trypanosome parasites

Article Title: The trypanosome ESCRT system possesses both novel components and under-recognised pan-eukaryotic features

Article References: Padilla-Mejia, N. E., Durante, I. M., Záhonová, K., Stříbrná, E., Heller, J., Dacks, J. B., Lukeš, J., & Field, M. C. (2026). The trypanosome ESCRT system possesses both novel components and under-recognised pan-eukaryotic features. BMC Biology. https://doi.org/10.1186/s12915-026-02730-4

Image Credits: AI Generated

DOI: 10.1186/s12915-026-02730-4

Keywords: ESCRT, endocytosis, trypanosomes, Trypanosoma brucei, Tom1, Vps23, flagellar pocket, protein trafficking, endosomes, eukaryotic evolution, VHS domain, FYVE domain